SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 2001-11-30
- Employees
- 5K
- Market Cap
- -
- Website
- https://www.luoxin.cn
A Phase I Study of LX22001 for Injection in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 70
- Registration Number
- NCT06561542
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Target Recruit Count
- 22
- Registration Number
- NCT05915871
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans
- Conditions
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-05-31
- Target Recruit Count
- 6
- Registration Number
- NCT05883306
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 561
- Registration Number
- NCT05577468
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-07-11
- Target Recruit Count
- 648
- Registration Number
- NCT05151328
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-04-25
- Target Recruit Count
- 400
- Registration Number
- NCT05010954
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Phase I Study of LX-039 Tablets
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2023-05-01
- Target Recruit Count
- 44
- Registration Number
- NCT04097756
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-04-15
- Target Recruit Count
- 261
- Registration Number
- NCT03615677
- Locations
- 🇨🇳
Shanghai First People's Hospital, Shanghai, Shanghai, China
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 291
- Registration Number
- NCT03591653
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.
- Conditions
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2018-05-30
- Target Recruit Count
- 38
- Registration Number
- NCT03458650
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China